The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $5.98

Today's change+0.01 +0.17%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $5.98

Today's change+0.01 +0.17%
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.

Orexigen Therapeutics Inc up (U.S.)$0.01

Orexigen Therapeutics Inc closed up Wednesday by (U.S.)$0.01 or 0.17% to (U.S.)$5.98. Shares have lost 6.27% over the last five days, but have gained 6.22% over the last year to date. This security has underperformed the S&P 500 by 7.15% during the last year.

Key company metrics

  • Open(U.S.) $5.95
  • Previous close(U.S.) $5.97
  • High(U.S.) $6.00
  • Low(U.S.) $5.73
  • Bid / Ask-- / --
  • YTD % change+6.22%
  • Volume997,564
  • Average volume (10-day)4,008,838
  • Average volume (1-month)3,238,402
  • Average volume (3-month)3,710,619
  • 52-week range(U.S.) $3.11 to (U.S.) $7.82
  • Beta2.50
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.56
Updated December 24 1:00 PM EST. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue31111
Total other revenue--------
Total revenue31111
Gross profit--------
Total cost of revenue--------
Total operating expense18242422
Selling / general / administrative7776
Research & development11171715
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income13-23-23-21
Interest income (expense), net non-operating-2-2-2-1
Gain (loss) on sale of assets--------
Other--------
Income before tax11-25-25-21
Income after tax11-25-25-21
Income tax, total--000
Net income11-25-25-21
Total adjustments to net income--------
Net income before extra. items11-25-25-21
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items11-25-25-21
Inc. avail. to common incl. extra. items11-25-25-21
Diluted net income11-25-25-21
Dilution adjustment--00--
Diluted weighted average shares130118109102
Diluted EPS excluding extraordinary itemsvalue per share0.09-0.21-0.23-0.21
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.09-0.21-0.23-0.21